Show simple item record

dc.contributor.advisorKolstrup, Nils
dc.contributor.authorLagerlöf, Anders Joakim
dc.date.accessioned2015-09-08T09:02:37Z
dc.date.available2015-09-08T09:02:37Z
dc.date.issued2015-05-29
dc.description.abstractNeuropathic pain is caused by damage or disease that affects the somatosensory nervous system, where the nerves react abnormal to small or no stimuli at all and produces pain. It is less understood than nociceptive pain arising from a healthy nervous system and hence is a notoriously hard condition to treat. Neuropathic pain tends to be chronic with an average duration of 7 years [1]. The cost to society and the implications for the patient in regard to comorbidity tends to be severe [2]. I decided to write a topical review to look closer at what evidence there is for the most commonly used antiepileptic drugs in the treatment of neuropathic pain (gabapentin, pregabalin, clonazepam, lacosamide, oxcarbazepine, phenytoin, valproic acid and zonisamide), what efficacy and what adverse effects one can expect.en_US
dc.identifier.urihttps://hdl.handle.net/10037/8023
dc.identifier.urnURN:NBN:no-uit_munin_7609
dc.language.isoengen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.rights.accessRightsopenAccess
dc.rights.holderCopyright 2015 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)en_US
dc.subject.courseIDMED-3950en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community pharmacy: 812en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsfarmasi: 812en_US
dc.titleAntiepileptic drugs for chronic neuropathic painen_US
dc.typeMaster thesisen_US
dc.typeMastergradsoppgaveen_US


File(s) in this item

Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)